Latest Trastuzumab Stories
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer.
The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV.
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status.
Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns about whether enough women are being offered these approaches.
The Vall d'Hebron Breast Cancer Unit, the Vall d'Hebron Institute of Oncology (VHIO) and SOLTI, an academic breast cancer research group are heading up a multi-center international study involving four Spanish and three North American research centers.